Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Alphabet Inc Class A (GOOGL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Alphabet Inc Class A — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Alphabet Inc Class A trades at $357.36 (market cap $4.35T). The key difference: Alphabet Inc Class A is far larger — about 109× Alnylam Pharmaceuticals, Inc.'s market cap, and Alphabet Inc Class A pays a 0.25% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | GOOGL | |
|---|---|---|
Market Cap | $39.89B | $4.35T |
Sector | Health | Media |
52-Week High | $491.22 | $402.62 |
52-Week Low | $278.09 | $180.19 |
Enterprise Value | $38.15B | $4.31T |
Dividend Yield | — | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Alphabet (GOOGL) trades at $357.18, down 0.48% on the day, with a neutral technical signal but strong fundamental performance. The company reported robust Q1 2026 earnings of $5.11 EPS, significantly beating expectations of $2.64, continuing a trend of earnings outperformance. Revenue growth accelerated to $402.84 billion in 2025 with net income margins expanding to 32.8%. Analyst consensus remains overwhelmingly bullish with 85% buy ratings and a $432.22 price target representing 21% upside potential.
Alphabet presents a compelling investment case driven by AI leadership, consistent earnings beats, and strong cash flow generation. Key risks include regulatory scrutiny, competitive pressures in search and cloud, and market volatility. The company's $7.24 billion net cash flow in 2025 and improving profitability metrics support continued growth, while recent YouTube price increases and AI infrastructure partnerships provide additional revenue catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →
